Ottimo Pharma Announces FDA Clearance of Investigational New Drug (IND) Application for OTP-01, a First-in-Class, Dual-Paratopic, Single-Agent, Anti-PD-1/VEGFR2 AntibodyLONDON and BOSTON, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Ottimo Pharma (“Ottimo”), an innovative, clinical-stage biotech company developing one-of-a-kind PD-1/VEGFR2 dual-paratopic antibodies to extend the lives of patients living with cancer, today announces the US Food and Drug Administration clearance of the investigational new drug (IND) application for its lead candidate OTP-01. The first patient has been dosed and recruitment is well underway. All manufacturing of OTP-01 is occurring solely in the US.
Ottimo Pharma Strengthens Board with Appointment of Roger Dansey, M.D. to its Board of DirectorsLONDON and BOSTON, April 10, 2025 (GLOBE NEWSWIRE) -- Ottimo Pharma (“Ottimo”), an innovative biotech company developing one-of-a-kind PD-1/VEGFR2 dual paratopic antibodies to extend the lives of patients living with cancer, today announces the appointment of Robert Dansey, M.D., a prominent leader in oncology research and drug development, to its board of directors.
